| 2023 | 2022 | 2021 | 2020 |
|---|
| Revenues | 1,317.67 | 1,510.55 | 2,178.63 | 1,680.36 |
| Expenses | 1,272.94 | 1,425.32 | 1,904.22 | 2,344.69 |
| Net Profit (Loss) | 13.43 | 53.04 | 812.03 | -299.07 |
| Assets | 1,368.33 | 1,544.11 | 1,677.19 | 1,556.62 |
| Liabilities | 843.71 | 1,037.70 | 1,284.30 | 2,298.25 |
| Shareholders' Equity | 524.62 | 506.42 | 392.89 | 734.04 |
| Operating | 39.32 | 223.60 | -52.97 | 315.66 |
| Investing | -27.50 | -58.68 | -101.07 | -3.04 |
| Financing | -115.50 | -155.01 | 273.39 | -331.56 |
| EPS (Baht) | 0.00 | 0.01 | 0.02 | -0.01 |
| GP Margin (%) | 33.60 | 33.22 | 33.58 | 32.28 |
| NP Margin (%) | 1.02 | 3.51 | 35.70 | -37.70 |
| D/E Ratio (x) | 1.61 | 2.05 | 3.27 | |
| ROE (%) | 2.60 | 11.80 | 144.11 | -56.52 |
| ROA (%) | 3.07 | 5.29 | 51.14 | -33.21 |
The Company focuses to operate in Medical Device business by Increasing product lines with both new products and expanding existing ones. The Company also emphasizes to achieve substantial growth in the medical device business, particularly in Medical Software and Hospital Infrastructure including specialized medical centers together with Collaborating on telemedicine systems and Electronic Medical Record (EMR) systems. In addition the Company plans to be engaged in Turnkey projects.
The runner-up award in the AKA group (consisting of ASEAN
countries, South Korea, and Australia) for being a representative
distributor with excellent performance in terms of sales volume,
orders, and overall operation as a GE Healthcare distributor.
On January 22, 2024, The Company had entering into a partnership with Worm Link Co., Ltd., a leading manufacturer and developer of video recording, Image Capturing and reporting systems of endoscopic surgeries “Endolink”. The Company was appointed as the authorized distributor and service provider of Endolink products in Thailand. Endolink is a technologically advanced product designed to support healthcare and enhance operational efficiency in endoscopic procedures, aligning with the demands of the digital era, both present and future.
Total Revenues of EFORL for the year 2023 was Baht 1,310 million, which decreased by 12% compared to the last year. This decline was primarily due to the delayed formation of the government, which resulted in the postponement of the approval of the annual government statement of expenditure. Since the main customers of the Company are government sectors, the Company was directly affected by the purchase order products from these customers. Consequently, the Company is currently engaged in negotiations with potential partners to introduce new products and expand product lines in order to boost revenues. Major products by customers in 2023 included: 1. Ventilators (Hamilton Medical) 2. Electroencephalography (Nihon Kohden) 3. Anesthesia Delivery System (GE Healthcare). In 2023, the gross margin was Baht 440 million, representing a decrease of 11% compared to the previous year. The net profit amounted to Baht 13 million
- April 2022, EFORL changed par value by the way of reverse stock split from THB 0.075 per share to THB 0.75 per share.
- July 2022, EFORL changed the paid-up capital from THB 2,998,398,712.50 or number of ordinary shares 39,978,649,500 shares to THB 2,998,398,735.00 or number of ordinary shares 3,997,864,980 shares resulting from the exercise of EFORL-W5 30 units to ordinary share 30 shares.
- November 2022, EFORL signs an distributor agreement with Advanced Sterilization Products (Thailand) Limited appointing EFORL as a distributor for STERRAD low-temperature sterilization products using innovation in hydrogen peroxide gas plasma (HPGP) sterilization technology which helps enhance the safety of medical instruments, patients, sterile processing staff, and environment, and trusted by Healthcare institutions in Thailand and around the world.
- March 2023, EFORL signs an distributor agreement with Kazem Machinery & Tool Co., Ltd. appointing EFORL as a sole distributor of Air Purifier Machines in Thailand and overseas.
- June 2023, EFORL changed its paid-up capital from THB 2,998,398,735, representing a total of 3,998,477,193 ordinary shares at a par value of THB 0.75 per share. This change was due to the exercise of warrants (EFORL-W5) amounting to 409,208 units and warrants (EFORL-W6) amounting to 203,005 units, totaling 612,213 units converted into common shares.
The Company is exposed to exchange rate fluctuations risks as it
imports products from overseas. However, the Company has
protected risk from the fluctuation in exchange rate by making
forward contract and call option (if any) together with the
negotiation with the suppliers to make orders in Thai Baht through
the representation of supplier in Thailand.
| as of 28/12/23 | EFORL | CONSUMP | mai |
|---|---|---|---|
| P/E (X) | 40.56 | 140.92 | 109.18 |
| P/BV (X) | 1.94 | 1.58 | 2.17 |
| Dividend yield (%) | - | 1.93 | 1.53 |
| 28/12/23 | 30/12/22 | 30/12/21 | |
|---|---|---|---|
| Market Cap (MB) | 999.62 | 1,359.27 | 7,995.73 |
| Price (B/Share) | 0.25 | 0.34 | 0.20 |
| P/E (X) | 40.56 | 19.68 | 10.02 |
| P/BV (X) | 1.94 | 2.78 | 22.28 |
